What AAVantgarde Bio does

AAVantgarde Bio s.r.l. is a clinical-stage biotechnology company founded in 2021 as a spin-off of the Telethon Institute of Genetics and Medicine (TIGEM) and the University of Naples 'Federico II', developing one-time subretinal gene therapies for inherited retinal disorders (IRDs) — specifically Stargardt disease (ABCA4 mutations) and retinitis pigmentosa associated with Usher Syndrome Type 1B (MYO7A mutations). The company is headquartered in Milan with operations in London and is led by CEO Natalia Misciattelli and founder/CSO Prof. Alberto Auricchio.

The company's core technology is two proprietary, AAV-based large-gene delivery platforms that overcome the ~4.7–5 kb cargo limit of conventional AAV vectors: the Dual Hybrid Platform, which splits a therapeutic transgene across two AAV8 vectors that reconstitute a full-length mature mRNA via ITR/HR-mediated concatemerization and splicing (used in AAVB-081 / LUCE-1 for Usher 1B); and the Intein-mediated Protein Trans-splicing Platform, which uses split inteins to reassemble large therapeutic proteins inside target cells (used in AAVB-039 / CELESTE for Stargardt). Both platforms have been validated in mice, pigs, non-human primates and human retinal organoids. The clinical pipeline comprises AAVB-081 (Phase 1/2 LUCE-1, fully enrolled) and AAVB-039 (Phase 1/2 CELESTE, IND-cleared), supported by the STELLA natural history study in ~120 Stargardt subjects. Pipeline placeholders AAVB-OPHTHA and AAVB-OTHER extend the platforms to additional IRDs and non-ophthalmic monogenic indications (inner ear, CNS).

AAVantgarde is currently pre-revenue. Funding to date totals approximately $202 million across a 2021 Sofinnova-Telethon seed, a €61M Series A in June 2023, and a $141M Series B in November 2025 co-led by Schroders Capital, Atlas Venture and Forbion, with new investors including Amgen Ventures. Future revenue is expected from commercialization of AAVB-081 and AAVB-039 and from platform out-licensing (a Dual Hybrid license for hereditary hearing loss has already been signed with a US company). Manufacturing is contracted to AGC Biologics; clinical operations span the US, UK and Europe; and the company partners with 14+ global patient advocacy organizations for trial recruitment and disease awareness.

Name

AAVantgarde Bio

Legal name

AAVantgarde Bio s.r.l.

Website

https://www.aavantgarde.com/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

AAVantgarde Bio is a clinical-stage biotechnology company developing one-time subretinal gene therapies for inherited retinal disorders — Stargardt disease and Usher Syndrome Type 1B — using proprietary Dual Hybrid and Intein AAV platforms that deliver large therapeutic genes exceeding conventional AAV packaging capacity.

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Gene therapy development
• Ophthalmic biotechnology
• Adeno-associated virus vectors
• Inherited retinal disorders
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-revenue clinical-stage development: AAVantgarde is currently pre-revenue, with no approved products. The company funds clinical development (LUCE-1, CELESTE, STELLA) entirely from venture capital and grants; future revenue is expected from commercialization of its lead gene therapies (AAVB-081 for Usher 1B and AAVB-039 for Stargardt) once approved, and from potential platform out-licensing to other indications.
2. Platform out-licensing (Dual Hybrid): The Dual Hybrid platform has been licensed to a US company for hereditary hearing loss applications, generating potential upfront, milestone, and royalty income. This represents an early-stage licensing/royalty revenue stream derived from the company's proprietary AAV delivery technology.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

AAVantgarde Bio is a clinical-stage biotechnology company developing investigational gene therapies for inherited retinal disorders (IRDs) using two proprietary dual-vector AAV delivery platforms — the Dual Hybrid Platform and the Intein Platform — that overcome the ~4.7–5 kb cargo limit of conventional AAVs to deliver large therapeutic transgenes such as MYO7A and ABCA4. The lead clinical programs are AAVB-081 (for retinitis pigmentosa associated with Usher Syndrome Type 1B) and AAVB-039 (for Stargardt disease), both pursued via subretinal administration of AAV8-based dual vectors.

Product overview

AAVantgarde Bio is a clinical-stage biotechnology company built around a platform-plus-candidates architecture: two proprietary large-gene AAV delivery platforms (the Dual Hybrid Platform and the Intein Platform) underpin a focused pipeline of investigational gene therapies. The Dual Hybrid Platform powers AAVB-081, the lead product for retinitis pigmentosa associated with Usher Syndrome Type 1B (Usher 1B), tested in the LUCE-1 Phase 1/2 trial; the Intein Platform powers AAVB-039, the second product for Stargardt disease, tested in the CELESTE Phase 1/2 trial and supported by the STELLA natural history study. The company is also extending its reach via two early pipeline placeholders — AAVB-OPHTHA (additional monogenic IRDs) and AAVB-OTHER (non-ophthalmic monogenic indications such as inner ear and CNS). The spin-off of Fondazione Telethon/TIGEM and University of Naples Federico II focuses the entire offering on restoring visual function and halting disease progression in IRDs caused by mutations in large genes that exceed conventional AAV packaging capacity.

Differentiator

Problem solved

Functional benefit

Brands

• Dual Hybrid Platform: Proprietary AAV-based large gene delivery platform that splits a therapeutic transgene across two vectors and reassembles it at the DNA level via splice donor/acceptor signals and a highly recombinogenic region; used in the AAVB-081 program for Usher 1B.
• Intein Platform
• AAVB-081
• AAVB-039

Products and services

• AAVB-081 AAVB-081 is AAVantgarde's lead investigational gene therapy product: an intra-retinal AAV8-based dual hybrid gene therapy delivering MYO7A, the gene associated with Usher Syndrome Type 1B (Usher 1B). It is being investigated in the LUCE-1 Phase 1/2 multicenter, open-label, dose escalation study for retinitis pigmentosa associated with Usher 1B.
• AAVB-039 AAVB-039 is AAVantgarde's second investigational gene therapy product: an intra-retinal AAV8-intein mediated gene therapy delivering ABCA4, the gene associated with Stargardt disease (STGD1), the most common inherited retinal disorder caused by mutations in a single gene. It is being investigated in the CELESTE Phase 1/2 study in the US.
• AAVB-OPHTHA AAVB-OPHTHA represents AAVantgarde's next pipeline program targeting additional monogenic inherited retinal diseases (IRDs) with high unmet need, intended to expand the company's ophthalmology franchise beyond Usher 1B and Stargardt.
• AAVB-OTHER AAVB-OTHER represents AAVantgarde's pipeline expansion into non-ophthalmic monogenic indications, exploring tissues outside the eye such as the inner ear and central nervous system using the company's large-gene delivery platforms.
• Dual Hybrid Platform The Dual Hybrid Platform is AAVantgarde's proprietary AAV-based large gene delivery technology that splits a therapeutic transgene across two AAV vectors that recombine at the DNA level via a proprietary highly recombinogenic region and ITR-mediated concatemerization, producing a full-length mature mRNA inside the cell nucleus. It powers the AAVB-081 program for Usher 1B and is licensable to third parties (e.g., licensed to a US company for hereditary hearing loss).
• Intein Platform The Intein Platform is AAVantgarde's proprietary AAV-based large gene delivery technology that uses two vectors each encoding one half of a target protein flanked by short split-intein sequences, enabling protein trans-splicing inside the cell to reconstitute large therapeutic proteins. It powers the AAVB-039 program for Stargardt disease and is licensable to third parties.

Quantifiable outcome

• 15 Usher syndrome patients treated to date via the Dual Hybrid approach in the LUCE-1 study, with a very good safety profile and early efficacy signal reported
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor, flagship and core.

• Idorsia (Board nomination of AAVantgarde CEO Natalia Misciattelli)minorOthers · 24 March 2026AAVantgarde CEO Natalia Misciattelli has been nominated by Idorsia for election to its Board of Directors at the May 2026 Annual General Meeting, reflecting her industry expertise rather than a commercial partnership between the two companies.
• AGC BiologicsflagshipStrategic or Co-development Partner · 21 November 2025Manufacturing agreement under which AGC Biologics will produce AAVantgarde's dual-vector gene therapies for inherited retinal diseases (Stargardt and Usher syndrome-related retinitis pigmentosa) using AGC's BravoAAV™ platform. The collaboration supports clinical development in the US, UK, and Europe.
• Telethon Institute of Genetics and Medicine (TIGEM)flagshipStrategic or Co-development Partner · 1 January 2021Foundational academic/research partner: AAVantgarde is a spin-off of TIGEM (Telethon Institute of Genetics and Medicine, a Telethon Foundation research centre in Pozzuoli, near Naples) and originated from research activities carried out there, including development of the Dual Hybrid and Intein AAV platforms by founder Alberto Auricchio.
• Fondazione TelethonflagshipStrategic or Co-development Partner · 1 January 2021Foundational partner: AAVantgarde Bio s.r.l. is described as a "Fondazione Telethon/UNINA spin-off company". Fondazione Telethon is a major Italian biomedical charity that has invested almost €600 million in funding over 2,700 rare-disease research projects. The Telethon Fund, managed by Sofinnova Partners, was a seed investor in AAVantgarde.
• University of Naples "Federico II" (UNINA)coreStrategic or Co-development Partner · 1 January 2021AAVantgarde is a joint spin-off of UNINA and TIGEM. Founder/CSO Professor Alberto Auricchio is Professor of Medical Genetics at University "Federico II" in Naples, Italy, and President of the European Society for Gene and Cell Therapy (ESGCT).
• US company (Dual Hybrid licensee for hereditary hearing loss)coreOEM/ Whitelabel/ Licensing PartnerAAVantgarde has licensed its Dual Hybrid AAV gene therapy platform to a US company for application in hereditary hearing loss, representing an early-stage platform out-licensing revenue channel beyond the company's lead ophthalmology pipeline.

Scale indicators7 records

Recent moves7 records

Expansion highlights1 record

Direct peers

• Spark Therapeutics: Pioneering ocular AAV gene therapy company (acquired by Roche in 2019) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutation). Direct comparable on AAV-based one-time subretinal gene therapy for IRDs with FDA Orphan and Breakthrough designations.
• Nightstar Therapeutics: Clinical-stage AAV gene therapy developer focused on inherited retinal diseases (choroideremia, X-linked retinitis pigmentosa), acquired by Biogen for ~$800M in 2019. Most direct late-stage peer in subretinal AAV gene therapy for IRDs and a key prior-art benchmark for AAVantgarde's commercialization path.
• Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (intravitreal AAV.7m8-aflibercept) for wet AMD and diabetic macular edema. Closely comparable ocular AAV gene therapy peer with shared regulatory designations (FDA Fast Track) and a similar enterprise-value profile to AAVantgarde at clinical-stage.
• MeiraGTx: Clinical-stage gene therapy company with multiple ocular programs (AAV-CNGB3, AAV-CNGA3 for achromatopsia, AAV-RPGR for X-linked retinitis pigmentosa) and in-house GMP manufacturing. Highly comparable peer given its portfolio of AAV-based therapies targeting IRDs and parallel regulatory trajectory.
• SparingVision: European clinical-stage biotech developing gene therapies for IRDs including retinitis pigmentosa (SPVN06, SPVN20). Closest European IRD gene therapy peer with comparable stage, fundraising profile (€75M Series B) and AAV-based approach.

Broad incumbents

• REGENXBIO: Clinical and commercial-stage AAV gene therapy company with a broad NAV Technology platform and multiple ophthalmology programs (RGX-314 for wet AMD/nAMD via subretinal and suprachoroidal routes). Larger incumbent with overlapping AAV vector manufacturing and ocular delivery capabilities and a public market benchmark for AAVantgarde's potential valuation.

Emerging players

• Coave Therapeutics: European clinical-stage AAV gene therapy company with programs in ophthalmology (RPGR for X-linked retinitis pigmentosa) and CNS, using engineered AAV capsids. Comparable European gene-therapy peer at similar stage with an overlapping IRD pipeline.
• ProQR Therapeutics: Clinical-stage RNA-editing company (Axonys Therapeutics spinoff focus) developing therapies for IRDs including Stargardt disease (ultevursen for ABCA4 mutations) and Usher syndrome. Adjacent modality peer targeting the same patient populations as AAVantgarde via antisense oligonucleotides rather than AAV gene replacement.
• Editas Medicine: Clinical-stage CRISPR gene-editing company that dosed the first in vivo CRISPR therapy (EDIT-101 for Leber congenital amaurosis 10, CEP290). Emerging modality peer that could compete with AAVantgarde's AAV approach for certain IRDs via in vivo editing.
• Beam Therapeutics: Clinical-stage base-editing company with programs in sickle cell disease, alpha-1 antitrypsin deficiency and ocular diseases; exploring in vivo base editing for ABCA4 (Stargardt). Represents the next-generation editing modality that could displace dual-AAV gene therapy approaches for AAVantgarde's lead indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aavantgarde-bio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AAVantgarde Bio